For the year ending 2025-12-31, CVSI had -$176K decrease in cash & cash equivalents over the period. -$516K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Product sales, net | 13,789 |
| Cost of goods sold | 7,037 |
| Gross profit | 6,752 |
| Research and development expense | 122 |
| Sales expense | 2,803 |
| Marketing expense | 1,666 |
| General and administrative expense | 3,153 |
| Benefit from reversal of accrued payroll taxes | -522 |
| Total operating expenses | 7,222 |
| Operating loss | -470 |
| Other expense, net | -479 |
| Loss before income taxes | -949 |
| Income tax expense (benefit) | 9 |
| Net loss | -958 |
| Depreciation and amortization | 192 |
| Stock-based compensation | 497 |
| Amortization of debt discount | 513 |
| Amortization of right of use assets | 238 |
| Gain in fair value of contingent consideration liabilities | 0 |
| Gain on debt extinguishment | 38 |
| Benefit from reversal of accrued payroll tax (note 12) | -522 |
| Deferred taxes | -3 |
| Other | 138 |
| Accounts receivable, net | -124 |
| Inventory | -827 |
| Prepaid expenses and other | -166 |
| Accounts payable and accrued expenses | -1,342 |
| Operating lease liability | -245 |
| Net cash flows used in operating activities | -407 |
| Purchases of property and equipment | 109 |
| Acquisition of business, net of cash acquired | 0 |
| Net cash flows used in investing activities | -109 |
| Proceeds from note payable | 1,650 |
| Debt issuance costs related to note payable | 90 |
| Repayment of note payable | 1,050 |
| Repayment of unsecured debt | 173 |
| Net cash flows provided by financing activities | 337 |
| Effect of exchange rate changes on cash | 3 |
| Net decrease in cash | -176 |
| Cash, beginning of year | 454 |
| Cash, end of year | 278 |
CV Sciences, Inc. (CVSI)
CV Sciences, Inc. (CVSI)